On the 18th of September 2026, the Zimbabwe Chapter of the International Papillomavirus Society (IPVS) was launched at Cresta Lodge Msasa. The event was attended by officials from the Ministry of Health and Child Care, clinicians, academics, researchers, advocates, industry, the private sector, and people with lived experience. The UZ-CTRC team from Cancer studies and Lab were part of the launch. As UZ-CTRC we are conducting studies on Human Papillomavirus (HPV) related cancers among men and women and contributing to the efforts to prevent and reduce the burden of HPV related cancers and diseases in Zimbabwe

Martha Tholana's story: UZ-CTRC's Community Advisory Board (CAB) member's journey of resilience, faith and strength against all odds. Her story is that of hope, perseverance and the power of embracing life. Read more in the link below... healthtimes.co.zw/beyond-the…

Prof. Mutsa Bwakura (left) and Dr. Allen Matubu (right) attending the ongoing AIDS Conference in Rio de Janeiro, Brazil. This event brings together scientists, policymakers, healthcare professionals, community leaders, civic society organizations, and development partners from around the world to discuss advancements and innovations in HIV prevention and treatment. The involvement of the University of Zimbabwe - Clinical Trials Research Centre demonstrates its ongoing commitment to promoting and advancing global scientific knowledge. In the photo, Dr. Allen Matubu and Prof. Mutsa Bwakura, discuss research findings from a recent study investigating plasma inflammatory proteins as predictive biomarkers for adverse pregnancy outcomes in women on ART in Zimbabwe.

UZ-CTRC hosted the Executive & Scientific leadership of the HIV Vaccine Trials Network at 3 Clinical Research Sites, represents a critical engagement between global scientists, educators, and community members dedicated to discovering and developing a safe and effective vaccine

#africa #africanhistory #AfricaDay #Ubuntu #AfricanUnity

Do you remember when you joined X? I do! #MyXAnniversary

#MothersDay2026 #HappyMothersDay #MomLife

Today, we celebrate the heartbeat of our organisation, our human capital. Happy Workers Day!

Today, we celebrate the strength, resilience, and unity that define our nation. As a health research organisation, we honour the progress Zimbabwe has made in advancing science, improving healthcare, and building a healthier future for all.

Last week, the University of Zimbabwe Clinical Trials Research Centre (UZ-CTRC) met with Dr. Sharon Achilles @sharonachilles, Deputy Director for Reproductive Health Technologies at the Gates Foundation. The meeting aimed to highlight UZ-CTRC's research capacity and explore collaborative opportunities in advancing reproductive health innovation.

Zimbabwe has marked a major milestone in HIV prevention with the rollout of lenacapavir, a long-acting injectable administered every six months. The introduction of this innovative prevention option represents a significant step forward in expanding choice and improving access to effective HIV prevention services. Commenting on this achievement, Dr Alan Smith, Senior Director for HIV Prevention TA Strategy, Medical Affairs at Gilead Patient Solutions, commended the Government of Zimbabwe: “It’s been truly inspiring to follow the recent news about advancements in HIV prevention in Zimbabwe—what an incredible achievement for the community and for everyone involved.” Dr Smith made these remarks during a recent Gilead familiarization visit hosted by @UZCTRC , where he engaged with key national stakeholders including Dr Owen Mugurungi, Director of AIDS and TB Programmes at the @MoHCCZim Ministry of Health and Child Care Zimbabwe, alongside @dr_Nyaradzo Dr Nyaradzo Mgodi and @Stranchi2 Dr Lynda Stranix-Chibanda from UZ-CTRC, and Dr Emmanuel Tachiwenyika of the Zimbabwe Health Interventions. Gilead Sciences is s the innovator, manufacturer, and regulatory sponsor of lenacapavir. Discussions during the visit focused on next steps to accelerate the scale-up of pre-exposure prophylaxis, including lenacapavir, and to strengthen comprehensive HIV prevention efforts across Zimbabwe. The engagement underscored the importance of continued collaboration between government, research institutions, and global partners to sustain progress toward ending HIV.

#FPCALiftOff2025 #WomenShapingGlobalHealth UZ-CTRC - Family Planning and Contraceptive Access Leadership Journey We’re thrilled to celebrate Dr Teacler Nematadzira, the St Marys CRS Leader on Lifting-Off from the WomenLift Health 2025 Family Planning and Contraceptive Access Leadership Journey! Dr Teacler has completed a year-long intensive leadership program designed for women leaders advancing reproductive health equity across Africa. The program connected her with a network of peers across the continent and provided coaching focused on authentic leadership and systems' influence in family planning. We're proud to have supported her through this journey and grateful to WomenLift Health for their commitment to developing women leaders who are shaping the future of Global Health. #fpcaliftoff2025 #womenshapingglobalhealth

UZ-CTRC congratulates the Ministry of Health and Child Care @MoHCCZim on the successful launch of Lenacapavir injection into Zimbabwe's National HIV Prevention Programme. This historic milestone, not only marks the introduction of a new biomedical intervention, it represents significant progress, innovation and collaborative commitment to ending HIV as a public health threat by 2030. #MOHCC #NAC

REQUEST FOR EXPRESSION OF INTEREST – Systems replication and backup services & Virtualization services - University of Zimbabwe Clinical Trials Research Center uz-ctrc.org/job/1696

The UZ-CTRC Principal Investigator, took time to share a thought for the longest serving cadre, Eunice Chifura, who went into retirement last week after serving the organisation for 27 years